ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)) by Braccioli, L et al.









Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10)   956 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
ERBB2 (v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, neuro/glioblastoma derived 
oncogene homolog (avian)) 
Luca Braccioli, Marilena V Iorio, Patrizia Casalini 
Molecular Targeting Unit, Experimenatal Oncology Department, Fondazione IRCCS Istituto Nazionale dei 
Tumori, Via Amadeo, 42, 20133 Milano, Italy (LB, MVI, PC) 
 
Published in Atlas Database: May 2011 
Online updated version : http://AtlasGeneticsOncology.org/Genes/ERBB2ID162ch17q11.html 
DOI: 10.4267/2042/46053 
This article is an update of :Casalini P, Iorio MV. ERBB2 (erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived 
oncogene homolog (avian) ). Atlas Genet Cytogenet Oncol Haematol 2005;9(1):6-12. 
 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Identity 
Other names: CD340; HER2; HER-2; HER-2/neu; 
MLN 19; NEU; NGL; TKR1 
Location: 17q12 
 
Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular 
Cytogenetics. 
Note 
Tyrosine-kinase receptor (RTK). The HER family of 
RTKs consists of four receptors: epidermal growth 
factor receptor (EGFR, also called HER-1 or erbB-1), 
HER-2 (also called erbB-2 or Neu), HER-3 and HER-4 
(also called erbB-3 and erbB-4, respectively). 
DNA/RNA 
Description 
Sequence length: 40522; CDS: 3678. 30 exons, 26 
coding exons; total exon length: 4816, max exon 
length: 969, min exon length: 48. Number of SNPs: 17. 
Polymorphisms: allelic variations at amino acid 
positions 654 and 655 of isoform (a) (positions 624and 
625 of isoform (b)) have been reported, with the most 
common allele B1 (Ile-654/Ile-655); allele B2 (Ile-
654/Val-655); allele B3 (Val-654/Val-655). This 
nucleotide polymorphism could be associated with 
development of gastric carcinoma and with breast 
cancer risk, particularly among younger women. 
Transcription 
Alternative splicing results in several additional 
transcript variants, some encoding different isoforms 
and others that have not been fully characterized. 
- mRNA transcript variant: this variant (1) represents 
the shorter transcript but encodes the longer isoform (a) 
(protein: erbB-2 isoform (a)). 
- mRNA transcript variant: this variant (2) (protein: 
erbB-2 isoform (b)) contains additional exons at its 5' 
end and lacks an alternate 5' noncoding exon, compared 
to variant (1). These differences result in translation 
initiation at an in-frame, downstream AUG and an 
isoform (b) with a shorter N-terminus compared to 
isoform (a). 
- mRNA transcript variant: herstatin HER2-ECD 
1300 bp alternative erbB-2 transcript that retains intron 
8. This alternative transcript specifies 340 residues 
identical to subdomains I and II from the extracellular 
domain of p185erbB-2 followed by a unique C-
terminal sequence of 79 aa encoded by intron 8. The 
herstatin mRNA is expressed in normal human fetal 
kidney and liver, but is at reduced levels relative to 
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p185erbB-2 mRNA in carcinoma cells that contain an 
amplified erbB-2 gene. 
- mRNA transcript variant: an alternative transcript 
form of the human homologous gene erbB-2, 
containing an in-frame deletion encompassing exon 19, 
has been detected in human breast carcinomas. 
- mRNA transcript variant: an alternative transcript 
form of the human homologous gene erbB-2, called 
HER2∆16, has been detected in human breast 
carcinomas. This splicing variant, contains an in-frame 
deletion and encodes a receptor lacking exon 16, which 
immediately precedes the transmembrane domain 
containing two cysteines. The loss of these cysteine 
residues might induce a change in the conformation of 
HER2 receptor extracellular domain that promotes 
intermolecular disulfide bonding and, in turn, 
homodimers capable of transforming cells. Ectopic 
expression of HER2∆16 promotes receptor 
dimerization, cell invasion, and trastuzumab resistant 
tumor cell lines. The potential metastatic and oncogenic 
properties of HER2∆16 were mediated through direct 
coupling of HER2∆16 to Src kinase. 
Protein 
Description 
erbB2 encodes a 185-kDa, 1255 amino acids, orphan 
receptor tyrosine kinase, and displays potent oncogenic 
activity when overexpressed. The proto-oncogene 
consists of three domains: a single transmembrane 
domain that separates an intracellular kinase domain 
from an extracellular ligand-binding domain. An 
aberrant form of HER2, missing the extracellular 
domain, so-called  
HER2p95, has been found in some breast cancers. 
HER2p95 is constitutively active because the external 
domain of these receptors acts as an inhibitor until they 
are bound by ligand. This isoform can cause resistance 
to trastuzumab, an antibody that works by binding to a 
domain in the external domain of HER2. HER2p95 
fragments arise through at least 2 different 
mechanisms: proteolytic shedding of the extracellular 
domain of the full-length receptor and translation of the 
mRNA encoding HER2 from internal initiation codons. 
Shedding of the ectodomain of HER2 generates a 95- 
to 100-kDa HER2 p95 membrane-anchored fragment. 
Translation of the mRNA encoding HER2 can be 
initiated from the AUG codon that gives rise to thefull-
length protein of 1255 amino acids or, alternatively, 
from 2 internal initiation codons at positions 611 and 
678, located upstream and downstream of the 
transmembrane domain, respectively. 
Expression 
HER2 protein is expressed in several human organs and 
tissues: normal epithelium, endometrium and ovarian 
epithelium and at neuromuscular level; prostate, 
pancreas, lung, kidney, liver, heart, hematopoietic cells. 
HER2 expression is low in mononuclear cells from 
bone marrow, peripheral blood (PB) and mobilized PB.
The higher expression has been found in cord blood-
derived cells. Quiescent CD34+ progenitor cells from 
all blood sources and resting lymphocytes are HER2 
negative, but the expression of this receptor is up-
regulated during cell-cycle recruitment of progenitor 
cells. Similarly, it increases in mature, hematopoietic 
proliferating cells, underlying the correlation betw en 





HER2 protein: schematic representation. Receptor tyrosin-kinases (RTKs) are cell surface allosteric enzymes consisting of: an 
extracellular ligand-binding domain (blue); a single transmembrane (TM) domain has an extensive homology to the epidermal grow factor 
receptor (brown); a cytoplasmic domain with catalityc activity (green). 
ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma  Braccioli L, et al. 





Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10)   958 
Function 
Activation and interactions 
For the other member of the HER family, ligand 
binding induces receptor homo- or heterodimerization, 
which is essential for TKs activation and subsequent 
recruitment of target proteins, in turn initiating a 
complex signaling cascade that leads into distinct 
transcriptional programs. There are several HER-
specific ligands. HER2, which apparently has no direct 
or specific ligand, plays a major coordinating role in 
the HER network because of its ability to enhance and 
stabilize the dimerization: each receptor with a specific 
ligand appears in fact to prefer HER-2 as its 
heterodimeric partner. HER-2-containing heterodimers 
are characterized by extremely high signaling potency 
because HER-2 dramatically reduces the rate of ligand 
dissociation, allowing strong and prolonged activation 
of downstream signaling pathways. 
Signaling and cellular 
The most important intracellular pathways activated by 
HER2 are those involving mitogen activated protein 
kinase (MAPK) and phosphatidylinositol-3 kinase 
(PI3K). HER2 expression in cancer, besides its rolein 
proliferation, enhances and prolongs survivals signals, 
associating up-regulation of this receptor to the 
malignant phenotype. At the same time, and depending 
on cellular status, the role of this receptor in cotr lling 
cell fate can also lead to differentiation and apoptosis. 
Physiological  
Role in development and differentiation: 
- HER2 has several non-oncogenic roles in regulating 
growth, differentiation, apoptosis and/or remodeling  
normal mammary glands. Dominant-negative forms of 
HER2 have significant defects in mammary 
development and lactation. 
- HER2 has an important role in development and 
function of heart. Cre-Lox technology to mutate erbB-2 
specifically in ventricular cardiomyocytes leads to a 
severe cardiomyopathy. This is inferred also by the 
adverse cardiac side effects observed in breast cancer 
patients treated with the monoclonal anti-HER2 Ab 
Trastuzumab. 
- HER2 has a role in control of Schwann cell 
myelination and it has been demonstrated that HER2 
signaling is also critical for oligodendrocyte 
differentiation in vivo. 
- HER2 has a dual role in both muscle spindle 
maintenance and survival of myoblasts. Muscle-
specific HER2 KO results in fact in viable mice with a 
progressive defect in proprioception due to loss of 
muscles spindles. 
Homology 
Homolog to avian erythroblastic leukemia viral (v-erb-






The Cancer Genome Project and Collaborative Group 
sequenced the erbB-2 gene from 120 primary lung 
tumors and identified 4% that had mutations within t e
kinase domain; in the adenocarcinoma subtype of lung
cancer, 10% of cases had mutations. 
In non small cell lung cancer (adenocarcinoma) the 
following erbB-2 mutations were found: 
insertion/duplication of GCATACGTGATG at 
nucleotide 2322 of the erbB-2 gene, resulting in a 4-
amino acid insertion (AYVM) at codon 774. Insertion 
of CTGTGGGCT at nucleotide 2335 of the erbB-2 
gene, resulting in a 3-amino acid insertion (VGS) 
starting at codon 779; a 2-bp substitution in the erbB-2 
gene, TT-CC at nucleotides 2263 and 2264, resulting in 
a leu755-to-pro (L755P) substitution. 
In lung cancer a C44645G transition in the erbB-2 gene 
that caused a pro1170-to-ala substitution (P1170A).  
In a glioblastoma a 2740G-A transition in the erbB-2 
gene that caused a glu914-to-lys substitution (E914K). 
In a gastric tumor a 2326G-A transition in the erbB-2 
gene that caused a gly776-to-ser (G776S) substitution. 
In an ovarian tumor, a 2570A-G transition in the erbB-





HER2 expression can be detected in blast cells from 
patients with hematological malignancies including 
acute lymphoblastic leukemia (ALL). It could be used 
as a potential target for the application of HER2-




HER2 is overexpressed in 25% to 40% of several 
human tumors and associated with the malignancy of 
the disease, high mitotic index and a shorter survival 
time for the patient. Overexpression of ErbB-2 is also 
associated with transitional cell carcinoma of the 
bladder. HER2 overexpression occurs in muscle-
invasive urothelial carcinomas of the bladder and is 
associated with worse survival; amplifications of erbB-
2 gene are also frequently linked to alterations of the 
TOP2A gene in bladder cancer. Furthermore, HER2 
overexpression and amplification in urothelial 
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Breast carcinoma 
Prognosis 
Normal tissues have a low content of HER2 membrane 
protein. Overexpression of HER2 is seen in 20% of 
breast and it confers worse biological behavior and 
clinical aggressiveness in breast cancer. Breast cancers 
can have up to 25 to 50 copies of the HER2 gene and 
up to a 40- to 100-fold increase in HER2 protein 
resulting in 2 million receptors expressed at the tumor 
cell surface. The differential HER2 expression between 
normal tissues and tumors helps to define HER2 as an 
ideal treatment target. Trastuzumab, the first treatm nt 
targeting HER2, is well tolerated in patients and has 
little toxicity because its effects are relatively specific 
for cancer cells overexpressing HER2. HER2 
amplification is a relatively early event in human breast 
tumorigenesis, occurring in almost 50% of in situ 
carcinomas. HER2 status is maintained during 
progression to invasive disease and to nodal and distant 
metastasis. The fact that only 20% of invasive breast 
cancers are HER2 amplified suggests that many HER2-
amplified in situ cancers never progress to the invasive 
stage. HER2 amplification defines a subtype of breast 
cancer with a unique signature of genes and this is 
maintained during progression. Some tumors lose 
HER2 expression following treatment with 
trastuzumab, presumably by selection of a HER2-
negative clone not killed by treatment. Conversely, 
HER2 may become positive in some initially negative 
tumors over time, especially after endocrine therapy 
targeting ER. Indeed, estrogen receptor has been shown 
to downregulate HER2 and, conversely, HER2 is able 
to downregulate ER expression. Therefore, it is not 
surprising that blocking ER might upregulate HER2 
and that blocking HER2 might upregulate ER. HER2-
amplified breast cancers have unique biological and
clinical characteristics. They have increased sensitivity 
to certain cytotoxic agents such as doxorubicin, relative 
resistance to hormonal agents, and propensity to 
metastasize to the brain and viscera. HER2-amplified 
tumors have an increased sensitivity to doxorubicin 
possibly due to coamplification of the topoisomeras-2 
gene, which is near the HER2 locus on chromosome 17 
and is the target of the drug. Half of HER2-positive 
breast cancers are ER positive but they generally hve 
lower ER levels, and many have p53 alterations. These 
tumors have higher proliferation rates and more 
aneuploidy and are associated with poorer patient 
prognosis. The poor outcome is dramatically improved 
with appropriate chemotherapy combined with the 
HER2-targeting drug trastuzumab. Overexpression of 
the erbB-2 gene is associated with tumor 
aggressiveness, and with patient responsiveness to 
doxorubicin, cyclophosphamide, methotrexate, 
fluorouracil (CMF), and to paclitaxel, whereas 
tamoxifen was found to be ineffective and even 
 
 
detrimental in patients with HER2-positive tumors. In  
Paget's disease of breast, HER2 protein overexpression 
is caused by amplification of the erbB-2 gene. HER2 
has a role in this disease of the breast, where the 
epidermis of the nipple is infiltrated by large neoplastic 
cells of glandular origin. It seems that binding of 
heregulin-alpha to the receptor complex on Paget cells
results in chemotaxis of these breast cancer cells. The 
isoforms HER2p95 and HER2∆16 are found in some 
breast cancers and the expression of these hyperactiv  




HER2 may be activated in the early stage of 
pathogenesis of cervical carcinoma in geriatric patients 
and is frequently amplified in squamous cell carcinoma 
of the uterine cervix. 
Childhood medulloblastoma 
Prognosis 
Overexpression of HER2 in medulloblastoma is 
associated with poor prognosis and metastasis and 
HER2-HER4 receptor heterodimerization is of 
particular biological significance in this disease. 
Colorectal cancer 
Prognosis 
Overexpression of HER2 occurs in a significant 
number of colorectal cancers. It was significantly 
associated with poor survival and related to tumor 
progression in colorectal cancer. 
Oral squamous cell carcinoma 
Prognosis 
E6/E7 proteins of HPV type 16 and HER2 cooperate to 
induce neoplastic transformation of primary normal 
oral epithelial cells. Overexpression of HER2 receptor 
is a frequent event in oral squamous cell carcinoma and 
is correlated with poor survival. 
Gastric cancer 
Prognosis 
HER2 amplification/overexpression does not seem to 
play a role in the molecular pathogenesis of most 
gastrinomas. However, mild gene amplification occurs 
in a subset of them, and overexpression of this receptor 
is associated with aggressiveness of the disease. HER2 
overexpression in patients with gastric cancer, andit 
has been solidly correlated to poor outcomes and a 
more aggressive disease. The overall HER2 positive 
rate is about 22%. HER2 overexpression rate in gastric 
cancer varies according to the site of the tumor. A 
higher overexpression rate (36%) was shown in 
gastroesophageal junction (GEJ) tumors in comparison 
to 21% in gastric tumors. 
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Germ-cell testicular tumor 
Prognosis 
A significant correlation was observed between HER2 




Data are still controversial about HER2 role in this 
carcinoma. Increased HER2 expression contributes to 
the development of cholangiocarcinogenesis into an 
advanced stage associated with tumor metastasis. In 
addition, overexpression of HER2 and COX-2 
correlated directly with tumor differentiation. However, 
other studies report that HER2 expression is associated 
with more favorable clinical features, such as a 
polypoid macroscopic type and absence of other organ 
involvement, and has been reported that the proporti n 
of HER2-positive cases in papillary adenocarcinoma is 
higher than in other histological types and is associated 
with an early disease stage. HER2 is preferentially 
expressed in well differentiated component, and it is 




HER2 is overexpressed in less than 20% of patients 
with non-small cell lung cancer (NSCLC) and studies 
have shown that overexpression of this receptor is 
correlated with a poor prognosis in both resected an  
advanced NSCLC. HER2 overexpression has an 
important function in the biology of NSCLC and may 




Higher frequency of HER2 expression has been 
observed in samples from patients with metastatic 
disease at presentation and at the time of relapse, nd it 
correlates with worse histologic response and decreased 
event-free survival. HER2 could be an effective target 
for the immunotherapy of osteosarcoma, especially the 
type with high metastatic potential. 
Ovarian cancer 
Prognosis 
HER2 overexpression varies from 9% to 32% of all 
cases of ovarian cancer and its overexpression is more 
frequent in advanced stage of ovarian cancer. 
Overexpression of HER2 in ovarian cancer cells leads 
to faster cell growth, higher abilities in DNA repair nd 
colony formation. A cross-talk between HER2 and 
estrogen receptor (ER) was identified in ovarian cacer 
cells. Estrogen has been proven to induce the 




Overexpression of HER-2 in pancreatic 
adenocarcinoma seems to be a result of increased 
transcription rather than gene amplification. The 
coexpression of HER2 oncogene protein, epidermal 
growth factor receptor, and TGF-beta1 in pancreatic 
ductal adenocarcinoma is related to the 
histopathological grades and clinical stages of tumors. 
The blockade of HER2 inhibits the growth of 
pancreatic cancer cells in vitro. HER2 overexpression 
was reported to accumulate in well differentiated 
pancreas adenocarcinomas whereas it is only 
infrequently found in poorly differentiated or 
undifferentiated tumors, in vivo and in vitro analyses 
have suggested that targeting HER2 might increase 
treatment effects of conventional chemotherapies of 
pancreas adenocarcinoma. However, unlike in breast 
cancer, the application of antibodies directed against 




HER2 plays pivotal roles in prostate cancer. Studies 
have shown that 25% of untreated primary tumors, 
59% of localized tumors after neoadjuvant hormone 
therapy, and 78% of metastatic tumors overexpressed 
HER2. Several lines of evidence have implicated HER2 
as a key mediator in the recurrence of prostate cancer to 
a hormone-refractory, androgen-independent tumor, 
which is the hallmark of prostate cancer progress. The
driving force for prostate cancer recurrence is the
reactivation of androgen receptor (AR), which is a type 
of nuclear receptors, activated by steroid hormone but 
ablated in hormonal therapy. Phosphorylation and 
reactivation of AR stimulate cancer cell growth and 
trigger tumor progression. It has been observed that 
overexpression of HER2 kinase enhanced AR function 
and hormone-independent growth in prostate tumor 
cells. HER2 activated AR through the MAPK pathway. 
Additionally, the HER2/HER3 dimmer increases AR 
protein stability and promotes the binding of AR to the 
promoter region of its target genes, resulting in AR 
activation in an androgen-depleted environment. 
Salivary gland tumor 
Prognosis 
Several results demonstrated significant positive 
staining of HER2 in the salivary tumorigenic tissue but 
not in the surrounding non-tumorigenic tissue, pointing 
to a biological role in the tumorigenic process. HER2 
amplification is present predominantly in tumors with 
high HER2 expression and seems to be the dominant 
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To be noted 
Note 
Possible therapeutic strategies: 1) growth inhibitory 
antibodies (like Trastuzumab), used alone or in 
combination with standard chemotherapeutics; 2) 
tyrosin kinase inhibitors (TKI); 3) active 
immunotherapy, because HER2 oncoprotein is 
immunogenic in some breast carcinoma patients; 4) 
dimerization inhibitor antibodies, like Pertuzumab: its 
binding to HER2 inhibits the dimerization of HER2 
with other HER receptors. 
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